Research
Hormonal
Modern GLP-1 receptor agonists (e.g., liraglutide) and combination therapies (e.g., phentermine/topiramate) offer significant, sustained weight loss with improved safety profiles compared to historical agents.
Modern obesity treatments like GLP-1 agonists (e.g., liraglutide) and combination therapies (e.g., phentermine/topiramate) are effective and safer than older drugs. They require medical supervision and are prescribed for specific patient profiles.
StrongSupportsHIGH confidence
The results of clinical trials of advanced therapeutic molecules, including gastrointestinal hormone receptor agonists, reinforce the belief that a breakthrough in the drug treatment of obesity is possible.
Why this rating
Based on multiple Phase III clinical trials and regulatory approvals.
Source
The history of the pharmacotherapy of obesity
M A Berkovskaya et al. · Problems of Endocrinology · 2025
narrative_review
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →